Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables (2016 - 2025)

Sunshine Biopharma's Receivables history spans 10 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Receivables fell 10.56% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, down 10.56%, while the annual FY2025 figure was $3.5 million, 10.56% down from the prior year.
  • Receivables reached $3.5 million in Q4 2025 per SBFM's latest filing, down from $4.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $4.2 million in Q3 2025 to a low of $22.0 in Q3 2022.
  • Average Receivables over 5 years is $2.2 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Receivables: plummeted 98.05% in 2022, then surged 9245895.45% in 2023.
  • A 5-year view of Receivables shows it stood at $7798.0 in 2021, then surged by 24421.07% to $1.9 million in 2022, then soared by 33.48% to $2.6 million in 2023, then surged by 51.56% to $3.9 million in 2024, then dropped by 10.56% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Receivables are $3.5 million (Q4 2025), $4.2 million (Q3 2025), and $3.6 million (Q2 2025).